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Abstract 
Objective 
Dementia with Lewy bodies (DLB) is associated with a range of cognitive and non-cognitive 
symptoms. We aimed to identify if some of these symptoms might aid early diagnosis of 
Lewy body disease in cases of mild cognitive impairment (MCI). 
 
Methods 
Lewy body MCI (MCI-LB; n=36), Alzheimer’s disease MCI (MCI-AD; n=21), DLB (n=36), AD 
(n=21) and control (n=20) participants were recruited. An interview-based questionnaire 
about the presence of symptoms thought to be associated with Lewy body disease was 
completed by participants with, where possible, their carer/relative. The prevalence of each 
symptom was compared between MCI-LB and MCI-AD and between established DLB and AD 
and a symptom scale based on these findings was devised. 
 
Results 
Fluctuating concentration/attention; episodes of confusion; muscle rigidity; changes in 
hand-writing, gait and posture; falls; drooling; weak voice; symptoms of REM sleep 
behaviour disorder (RBD)  and misjudging objects were more common in MCI-LB compared 
with MCI-AD, and also in DLB compared with AD. Hyposmia, tremor, slowness and 
autonomic symptoms were not specific to Lewy body disease. RBD and hyposmia were 
reported to develop several years prior to the onset of cognitive symptoms in Lewy body 
disease. A ten-point symptom scale differentiated between MCI-LB and MCI-AD with a 
sensitivity of 83% and a specificity of 100%. 
 
Conclusions 
Drooling, misjudging objects and symptoms related to parkinsonism, fluctuating cognition 
and RBD may be the most characteristic symptoms of MCI-LB. Slowness, tremor, autonomic 
symptoms and hyposmia are all common in MCI-LB but are not specific to the disease. 
 
Word count: 249 
 
  
Introduction 
Dementia with Lewy bodies (DLB) is the second most common type of neurodegenerative 
dementia after Alzheimer’s disease (AD), accounting for 7.5% of cases in secondary care 
(Vann Jones and O'Brien 2014). In 2005, International Consensus Criteria identified 
spontaneous motor parkinsonism, recurrent visual hallucinations, cognitive fluctuations, 
REM sleep behaviour disorder (RBD) and neuroleptic sensitivity as symptoms diagnostic of 
DLB, with an additional biomarker of reduced striatal dopaminergic innervation on PET or 
SPECT imaging (McKeith, et al. 2005). A range of other symptoms including repeated falls 
and syncope, unexplained loss of consciousness, hallucinations in non-visual modalities, 
delusions, depression and autonomic dysfunction were identified as being commonly 
present but of unknown diagnostic specificity.  
The varied nature of symptoms associated with DLB is likely to reflect the widespread 
deposition of Lewy body pathology in both the peripheral and central nervous systems. Sites 
such as the olfactory bulb and autonomic nervous system may be early sites of pathology in 
many cases (Beach, et al. 2009; Beach, et al. 2010). This raises the possibility of identifying 
LB disease in its early stages, prior to the development of dementia, through non-cognitive 
symptoms such as hyposmia, constipation and postural hypotension. 
Prospective clinical studies and post-mortem studies have reported that the diagnostic 
symptoms of DLB may already be present in the MCI phase of the disease (Cagnin, et al. 
2015; Ferman, et al. 2011; Ferman, et al. 2013; Fujishiro, et al. 2008; Yoon, et al. 2015). In 
particular RBD appears to be the most common and earliest-developing diagnostic symptom 
in this phase (Ferman et al. 2011). Retrospective studies based on symptom questionnaires 
have replicated these findings, with visual hallucinations, gait problems, tremor/stiffness, 
falls and sleep symptoms including RBD reported as more common in early stages of disease 
in DLB than AD, in addition to other symptoms such as hyposmia and constipation (Auning, 
et al. 2011; Chiba, et al. 2012; Donaghy, et al. 2015).  
This study investigated the prevalence of a broad range of symptoms associated with Lewy 
body disease in the mild cognitive impairment phase (MCI-LB) compared with MCI-AD. The 
same symptoms were also examined in patients with established DLB and AD to compare 
the findings. The aim was to identify symptoms that might be useful to clinicians and 
researchers to help identify MCI-LB and distinguish it from MCI-AD. 
 
Methods 
Participants 
DLB, AD, MCI-LB, MCI-AD and control subjects were recruited prospectively from secondary 
care services in the North of England. Control participants were recruited through a 
research case register or were partners of participants.  
Dementia participants were ≥60 years old and had a diagnosis of probable dementia with 
Lewy bodies or probable Alzheimer’s disease confirmed by two clinicians based on current 
diagnostic criteria (McKeith et al., 2005, McKhann et al., 2011), with an MMSE score ≥12. 
MCI participants were recruited for a study investigating prodromal DLB in which all 
participants had to have a possible symptom of Lewy body disease to be recruited to the 
study (e.g. tremor, unusual visual experiences, daytime sleepiness, sleep disturbance). All 
participants fulfilled criteria for all-cause MCI (Albert, et al. 2011), had an MMSE >20 and 
Clinical Dementia Rating score of ≤0.5.  
The diagnosis of MCI and the presence or absence of diagnostic symptoms of Lewy body 
disease as defined by consensus criteria (McKeith et al. 2005) was determined by a three 
clinician panel (PD, AT, JPT). Following the clinical and cognitive examination two clinicians 
rated whether the core and suggestive diagnostic symptoms of DLB were present in each 
participant. If there was disagreement between these two raters, the third clinician made 
the final decision. MCI subjects had 123I-FP-CIT SPECT but classification of the presence or 
absence of diagnostic symptoms was carried out blind to FP-CIT imaging results. Participants 
that were found to have no core or suggestive diagnostic features of Lewy body disease and 
had a negative 123I-FP-CIT SPECT fulfilled the clinical criteria for MCI-AD (Albert et al. 2011). 
MCI participants with two or more International Consensus Criteria Core or Suggestive 
Features (McKeith et al. 2005) were classified as Lewy body MCI (MCI-LB). When 
parkinsonian symptoms were present, participants were only included if the onset of these 
was after, or less than one year prior to the onset of cognitive symptoms. Participants with 
only one core or suggestive feature were excluded from further analysis. 
Control participants had an MMSE ≥26 and no evidence of MCI or dementia. Participants 
were excluded if they had a major concurrent psychiatric illness; severe physical illness that 
would limit their ability to fully participate in the study; a history of other significant 
neurological illness including clinical stroke or current treatment with any investigational 
agent. 
 
All participants with capacity gave their written informed consent to take part in the study. 
In the case of participants with dementia who lacked capacity their participation in the 
study was discussed with a consultee in accordance with the Mental Capacity Act. The study 
received ethical approval from the National Research Ethics Service Committee North East - 
Newcastle & North Tyneside 2 (Research Ethics Committee Identification Numbers: 
13/NE/0064, 12/NE/0290). 
 
Clinical Assessment 
All patients were assessed by the equivalent of a Board Certified Psychiatrist, who carried 
out a physical and neurological examination. Quantitative scales were used to assess 
neuropsychiatric symptoms (Geriatric Depression Scale (D'Ath, et al. 1994), Clinician 
Assessment of Fluctuations (Walker, et al. 2000), Dementia Cognitive Fluctuations Scale 
(DCFS) (Lee, et al. 2014), Neuropsychiatric Inventory (Cummings, et al. 1994)), parkinsonism 
(Revised Unified Parkinson’s disease Rating Scale Motor Sub-scale (Goetz, et al. 2008)) and 
level of functional impairment (Instrumental Activities of Daily Living Scale (Lawton and 
Brody 1969)). These assessments were used by the diagnostic panels detailed above to help 
determine each participant’s diagnosis.  
 
The Lewy Body Symptom Questionnaire 
Participants (with a relative or carer when possible) were interviewed and asked whether 
they experienced each of the symptoms listed in Table 1. The symptom list was adapted 
from an early version of the Lewy Body Dementia Association (LBDA) Comprehensive 
Symptom Checklist (an updated version of which is available at: 
www.lbda.org/content/comprehensive-lbd-symptoms-checklist). The checklist was 
developed by the LBDA to help people with Lewy body dementia and their carers identify 
symptoms that can then be reported to their physician during appointments.  
The interviewer asked if each individual symptom was present. Efforts were made to ensure 
the participants understood the question (e.g. ensuring that they understood that rigidity 
referred to muscles and not joints). In accordance with the purpose of the checklist, where 
participants understood the question their response was accepted without interpretation by 
the interviewer (e.g. including affirmative responses to ‘seeing things that are not present’ 
even if this seemed to refer to a misidentification rather than a hallucination). Where a 
symptom was present, participants were asked to estimate how long the symptom has been 
present for. 
Some questions were changed or added after commencing the studies, reflecting changes to 
the LBDA Checklist (e.g. weak voice, balance problems, frequent falls, anxiety, reaction to 
medications) and new evidence on visual symptoms in DLB (Jefferis, et al. 2013).  As a result, 
the number of respondents differed between questions. The minimum number of 
respondents for each symptom was 29 for MCI-LB, 19 for MCI-AD, 20 for AD, 32 for DLB and 
14 for controls. Sexual dysfunction was part of the original symptom checklist but in a large 
proportion of cases it was not felt appropriate to enquire about this during the interview 
(e.g. a widow/widower of several years attending with their son/daughter). Due to 
insufficient data this symptom was not analysed.  
 
TABLE 1 HERE 
 
Statistics 
Two comparisons were carried out for each symptom – MCI-LB v. MCI-AD and DLB v. AD. 
Control figures are included as a reference. Chi-squared and Fischer’s Exact tests were used 
with an unadjusted α=0.05 for each comparison. To reduce the risk of Type 1 errors, 
symptoms were only considered significant if they were found to be significantly more 
common in both Lewy body groups (MCI-LB and DLB) compared to their respective 
Alzheimer’s groups (MCI-AD and AD). 
 
Results 
Group demographics are displayed in Table 2. The MCI-LB group was more likely to be male 
than the MCI-AD group, there was no such difference between DLB and AD as these groups 
were matched for gender. There were no significant differences in age or overall level of 
cognitive impairment between the comparator groups (i.e. MCI-LB v. MCI-AD, and DLB v. 
AD). MCI-LB participants were more likely to live with their informant and have daily contact 
with them than MCI-AD participants. 
 
TABLE 2 HERE 
 
The proportion of participants from each group experiencing each symptom is displayed in 
Table 3. Symptoms that were significantly more common in both MCI-LB than MCI-AD and 
in DLB than AD were: fluctuating attention and concentration, unexplained episodes of 
confusion, rigidity or stiffness in muscles, shuffling walk, change in handwriting, drooling, 
frequent falls, change in posture, weak voice, symptoms of REM sleep behaviour disorder 
and difficulty moving around due to misjudging where objects are. Three further symptoms 
were significantly more common in DLB than AD and approached statistical significance in 
the MCI comparison: slowness of movement (p=0.079), loss of smell (p=0.053) and seeing 
things that are not present (p=0.052).The reported time of onset of these symptoms relative 
to the onset of memory impairment in the Lewy body groups is reported in Table 4. The 
earliest symptoms reported for both groups were loss of sense of smell and symptoms of 
RBD. Participants in the MCI-LB cohort also reported muscle stiffness/rigidity as an early 
feature, though it should be noted that only 28% of respondents reported this symptom. 
Other symptoms were reported to develop after the onset of memory problems. 
 
TABLE 3 HERE 
 
TABLE 4 HERE 
 
Apathy and excessive daytime sleepiness were more common in MCI-LB than MCI-AD, but 
were not more common in DLB than AD due to the higher prevalence of these symptoms in 
AD than in the MCI-AD group. 
Several symptoms were significantly more common in DLB than AD, but not significantly 
more common in MCI-LB compared with MCI-AD (p>0.10). These were disorganised speech, 
slack facial expression, balance problems, hearing things not present, other hallucinations, 
constipation and double vision. 
In the dementia groups, the DLB cohort were likely than AD to report significant 
improvement (42% v 15%) or minimal improvement (29% v 10%) in response to 
cholinesterase inhibitors/memantine (p=0.01 DLB v AD). 54% of 13 MCI-LB participants 
reported significant improvement and 15% reported minimal improvement. There were 
insufficient volunteers treated with cholinesterase inhibitors/memantine in the MCI-AD 
group to compare responses. 
 
In a post-hoc analysis, symptoms with a prevalence of >50% in DLB and <20% in AD were 
identified (Table 5). The aim was to identify symptoms that were common in LB disease and 
specific to this disorder. Ten symptoms were identified. Following this, the number of these 
symptoms present in each MCI participant was calculated to investigate the ability of these 
symptoms to differentiate between MCI-LB and MCI-AD. 
The mean score in MCI-LB (n=29) was 4.1±1.9, compared with 0.7±0.7 in MCI-AD (n=19). 
Using a threshold of >1 this 10-point score yielded a sensitivity of 90% and a specificity of 
84% to differentiate MCI-LB from MCI-AD (Area under the Receiver Operating Characteristic 
(AUROC)=0.87; 95% Confidence Interval (CI)=0.75-0.99). A threshold of >2 gave a sensitivity 
of 83% and a specificity of 100% (AUROC=0.91; 95% CI=0.83-0.999). A threshold of >3 
yielded a sensitivity of 62% and a specificity of 100% (AUROC=0.81; 95% CI=0.69-0.93). 
 
TABLE 5 HERE 
 
Discussion  
Symptoms reflecting cognitive fluctuations, motor parkinsonism and REM sleep behaviour 
disorder were more common in LB disease than Alzheimer’s disease, both in the early and 
later stages. These features are used to diagnose DLB and MCI-LB, and therefore by 
definition will be more common in these groups. However not all symptoms relating to 
these diagnostic features are specific to the disease. Our data identified which specific 
symptoms are most useful in distinguishing DLB and MCI-LB from AD and MCI-AD. For 
instance, rigidity or stiffness in muscles, frequent falls and weak voice were specific 
symptoms of motor parkinsonism (≤11% in AD and MCI-AD). Conversely, tremor, slowness 
of movement, change in handwriting and problems with balance were often reported in AD 
and MCI-AD (≥38%). Interestingly, drooling and misjudging objects were also specific to 
Lewy body disease despite not being directly related to diagnostic features. 
 
‘Seeing things that were not present’ was commonly reported in both the MCI-LB and MCI-
AD groups. The MCI-AD group were judged by a three-clinician diagnostic panel not to have 
the typically ‘well-formed and detailed’ visual hallucinations that constitute a diagnostic 
feature of DLB. Often the symptoms reported were misidentification phenomena, occurred 
in low light or were simple hallucinations such as flashes of light. These phenomena are 
probably less frequent in the general MCI-AD population than in our cohort that was 
enriched with possible Lewy body symptoms. However, this highlights the importance of 
assessment by an experienced clinician to properly characterise visual symptoms. 
 
Supportive Features of DLB 
Repeated falls and syncope, unexplained loss of consciousness, hallucinations in other 
modalities, delusions, depression and autonomic dysfunction are included in the 2005 
International Consensus Criteria as Supportive Features of Lewy body disease that are 
commonly present but without proven diagnostic specificity (McKeith et al. 2005). Our data 
generally supports this decision. Frequent falls were significantly more common in the LB 
groups but dizziness or fainting was common in all disease groups. Transient loss of 
consciousness, delusions and depression did not differentiate between Lewy body disease 
and Alzheimer’s disease. Auditory and other hallucinations were more common in DLB than 
AD, but the overall prevalence was relatively low in both LB groups. 
 
Hyposmia and Autonomic Symptoms 
In contrast with a previous retrospective symptom study we did not find that loss of sense 
of smell, constipation and dizziness differentiated between MCI-LB and MCI-AD (Chiba et al. 
2012). Our symptom of ‘dizziness or fainting’ was different to the ‘orthostatic dizziness’ 
reported in that study. Our rates of loss of sense of smell and constipation were similar to 
Chiba and colleagues, but the rates of these symptoms in MCI-AD and controls were higher 
in our cohort. The difference in constipation may reflect differences in dietary habits in the 
UK compared with Japan, or other cultural differences that make the reporting of 
constipation more likely. Though loss of sense of smell is a common feature of Lewy body 
disease, it may also be a marker for early Alzheimer’s disease (Devanand, et al. 2015) and is 
therefore unlikely to be a specific marker for either disease. 
 
Duration of symptoms 
Only the symptoms of RBD and hyposmia had a reported time of onset before the onset of 
memory impairment in both MCI-LB and DLB. Other symptoms tended to develop 1-2 years 
after the onset of memory loss. Previous evidence from longitudinal studies has identified 
RBD as an early marker or risk factor for the later development of synucleinopathies such as 
DLB, PDD and multi-system atrophy (Iranzo, et al. 2013).  
 
Symptoms more common in MCI-LB than MCI-AD, but not more common in DLB than AD 
Apathy and excessive daytime sleepiness were significantly more common in MCI-LB than 
MCI-AD. These symptoms may be useful in identifying MCI-LB, but it should be borne in 
mind that even in MCI-AD apathy (19%) and daytime sleepiness (29%) were not uncommon. 
 
Symptoms more common in DLB than AD, but not more common in MCI-LB than MCI-AD 
In addition to constipation, the symptoms of disorganised speech, balance problems, slack 
facial expression, non-visual hallucinations and double vision were significantly more 
common in DLB than AD, but the same difference was not observed in the MCI phase. These 
findings may be due to Type 1 errors or these symptoms may manifest at a later stage of the 
disease in DLB.  
  
Differentiating MCI-LB from MCI-AD using a 10-point symptom scale 
A 10 symptom scale was developed by identifying symptoms that were specific (>80%) and 
relatively sensitive (>50%) to identify DLB compared with AD. This was then applied to the 
MCI groups and was found to accurately discriminate between MCI-LB and MCI-AD. There is 
clearly some circularity here, as six of the ten symptoms directly address diagnostic 
symptoms (RBD, visual hallucinations and fluctuations) that are used to classify participants 
as MCI-LB.  However, brief assessment scales to identify possible Lewy body disease may be 
useful to highlight at-risk cases to clinicians, or to aid recruitment to research studies. A 
previous scale incorporating findings from physical examination for signs of parkinsonism 
and autonomic features has been shown to reliably identify Lewy body diseases (Galvin 
2015). The symptom questionnaire presented here does not incorporate the findings of 
clinical examination and therefore may be used in different ways. Clearly the questionnaire 
is not comparable to a clinical history and examination by an experienced clinician. We 
envisage that such screening questions may be used in initial memory clinic appointments 
to highlight the need for further assessment or investigation for diagnostic features of DLB 
and as brief and easily administered questionnaire to identify potential recruits for research 
studies in DLB and MCI-LB. Sensitivity may be the priority in the former scenario, whereas 
specificity may be more important in the latter, particularly where larger populations are 
being screened. The threshold used should be appropriate to the situation. 
 
Strengths and limitations 
This is the first cohort to compare the prevalence of a comprehensive range of symptoms 
between Lewy body disease and Alzheimer’s disease in both the MCI and dementia phases. 
The sample size is large enough to detect large differences, but may not detect small 
differences that exist between the two diseases. However, small differences in symptom 
rates are unlikely to be clinically useful in differentiating MCI-LB from MCI-AD. 
In order to reduce the risk of Type 1 errors symptoms were only considered significant when 
they were significantly more common both in MCI-LB compared with MCI-AD and in DLB 
compared with AD. Apathy and daytime sleepiness were found to be significantly more 
common in MCI-LB than MCI-AD but not significantly more common in DLB than AD. These 
symptoms may develop later in AD than DLB and therefore may still be useful when 
identifying MCI-LB. This will be tested in independent cohorts.   
The 10-point symptom scale was developed and tested in independent samples. As it was 
developed in a dementia group it may have missed some symptoms that are specific only to 
the early stages of disease, but it may mean the scale is robust across the early to moderate 
stages of the disease. This will also be tested in future independent samples.  
Unsurprisingly MCI-LB and DLB participants were more likely to be taking levodopa. This 
may have reduced the difference in reported parkinsonian symptoms between LB and AD 
groups. It is possible the side-effects of levodopa medication could contribute to other 
reported symptoms such as confusion. MCI-LB participants were more likely to live with 
their informant and see them daily. This may have made it more likely for symptoms such as 
RBD and fluctuations to be detected in this group, as they are rarely reported by the 
individual themselves. It is possible that such features may have been missed in some of the 
MCI-AD group.  
Participants in the MCI cohort were recruited on the basis of suspected symptoms of Lewy 
body disease. After a thorough assessment, including a clinical review with a board-certified 
equivalent psychiatrist, the diagnostic panel found that some of these participants did not 
have any Lewy body diagnostic symptom as defined by International Consensus Criteria 
(McKeith et al. 2005) and fulfilled criteria for MCI-AD. The reported symptom rates of this 
group may be higher than in a non-selected MCI-AD cohort. Though this may have made 
differences between the MCI groups more difficult to detect, it increases the robustness of 
our positive findings. MCI participants had 123I-FP-CIT SPECT imaging to confirm diagnosis; 
this was only available for dementia participants if it had been carried out as part of their 
routine clinical care. CSF protein levels were not available. 
The diagnosis of MCI-LB has face validity but has not yet been validated against pathological 
examination. Longitudinal follow-up of these patients will confirm rates of conversion to 
dementia and their final clinical diagnosis. 
 
Conclusions 
The following symptoms are more common in MCI-LB than MCI-AD: fluctuating attention 
and concentration, unexplained episodes of confusion, rigidity or stiffness in muscles, 
shuffling walk, change in handwriting, drooling, frequent falls, change in posture, weak 
voice, symptoms of REM sleep behaviour disorder and difficulty moving around due to 
misjudging where objects are. Slowness of movement and tremor are commonly reported in 
AD and MCI-AD and therefore may not be useful symptoms for identifying motor 
parkinsonism in Lewy body disease. Similarly, though autonomic symptoms and loss of 
sense of smell are common in LB disease, they are not sufficiently specific to be useful as 
diagnostic symptoms. Hyposmia and symptoms of RBD may be present for a substantial 
time prior to the development of cognitive complaints in Lewy body disease.  
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Table 1. The Symptom Questionnaire 
Cognitive Symptoms 
Memory 
Problem Solving 
Planning 
Fluctuating changes in concentration and 
attention 
Disorganised speech and conversation 
Unexplained episodes of confusion 
 
Parkinson’s Symptoms 
Rigidity or stiffness in muscles 
Shuffling walk 
Tremor 
Slowness of movement 
Change in Handwriting 
Slack facial expression 
Drooling 
Loss/reduction of sense of smell 
Balance problems 
Frequent falls 
Change in posture 
Weak voice 
 
Behaviour/mood changes 
Seeing things that are not present 
Hearing things that are not present 
Depression 
Apathy (loss of interest and drive)  
Delusions (false beliefs) 
Hallucinations in other senses (e.g. touch or 
smell) 
Anxiety 
 
Sleep Symptoms 
Troubled by vivid dreams 
Troubled by nightmares 
Had involuntary movements of arms and legs 
Acting out dreams, sometimes violently 
Cried out during sleep 
Excessive daytime sleepiness 
Transient loss of consciousness/unexplained 
blackouts 
Insomnia 
Restless legs syndrome 
 
Autonomic Dysfunction 
Dizziness, light-headedness or fainting 
Sensitivity to heat or cold 
Urinary incontinence 
Constipation 
 
Visual Symptoms 
Painful/dry eyes 
Double vision 
Difficulty reading (because words and letters 
move around the page) 
Misjudging objects (have difficulty moving 
around because you misjudge where objects are) 
 
Perceived response to Cholinesterase 
Inhibitors/Memantine 
Significant improvement 
Minimal improvement 
No change 
Worse 
Table 2. Group Demographics 
 Control MCI-AD MCI-LB 
 
AD DLB 
 
 
Mean (SD) Mean (SD) Mean (SD) 
p 
MCI-AD v. MCI-LB 
Mean (SD) Mean (SD) 
p 
AD v. DLB 
n 20 21 36 
 
21 36 
 
Age 75.9 (7.3) 78.5 (6.4) 75.3 (7.6) 0.11 76.3 (6.9) 75.7 (6.3) 0.71 
Gender (% female) 20 67 33 0.02 24 14 0.47 
MMSE Total 29.1 (0.9) 26.5 (2.1) 26.3 (2.3) 0.94 20.5 (4.7) 21.5 (4.6) 0.49 
AChI (%) 0 24 42 0.17 100 97 1 
Levodopa (%) 0 0 22 0.02 0 36 0.001 
Informant present 
(%) - 86 94 0.35 100 100 - 
Daily contact with 
informant (%) - 57 86 0.01 76 92 0.13 
Live with 
informant (%) - 52 78 0.047 71 83 0.33 
AChI = On treatment with acetylcholinesterase inhibitor; Levodopa = on treatment with levodopa.  
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Table 3. The percentage of patients experiencing each symptom  
 
CTRL 
(%) 
MCI-AD 
(%) 
MCI-LB 
(%) 
P 
MCI-AD v. 
MCI-LB 
AD 
(%) 
DLB 
(%) 
P 
AD v DLB 
Cognitive Symptoms 
Memory 15 95 94 1 100 89 0.29 
Problem Solving 0 14 36 0.08 67 71 0.77 
Planning 0 29 44 0.24 76 80 0.75 
Fluctuating conc./att. 5 10 39 0.02 10 69 <0.001 
Disorganised speech 0 14 33 0.12 10 37 0.02 
Episodes of confusion 0 0 28 0.01 5 54 <0.001 
Symptoms associated with Parkinson’s disease 
Rigidity or stiffness 10 0 28 0.01 5 36 0.01 
Shuffling walk 5 19 53 0.01 29 86 <0.001 
Tremor 20 48 50 0.86 48 72 0.06 
Slowness of movement 0 43 67 0.08 43 83 0.002 
Change in handwriting 35 38 75 0.01 38 89 <0.001 
Slack facial expression 0 0 14 0.15 14 54 0.003 
Drooling 10 10 53 0.001 19 80 <0.001 
Loss of Smell 20 19 44 0.05 29 63 0.01 
Balance problems 13 53 63 0.46 40 71 0.02 
Frequent Falls 0 11 43 0.02 5 31 0.04 
Change in posture 20 29 67 0.01 38 82 0.001 
Weak Voice 7 11 41 0.02 5 53 <0.001 
Neuropsychiatric Symptoms 
Seeing things 5 24 50 0.05 5 78 <0.001 
Hearing things 0 5 11 0.64 5 29 0.04 
Depression 0 14 31 0.17 19 22 1 
Apathy 0 19 47 0.03 48 47 1 
Delusions 0 0 0 1 5 17 0.24 
Other Hallucinations 5 5 11 0.65 5 28 0.04 
Anxiety 5 24 26 0.83 19 23 1 
Sleep Symptoms 
Vivid dreams 5 14 22 0.73 5 6 1 
Nightmares 5 5 22 0.13 10 11 1 
Involuntary movements 10 0 56 <0.001 5 54 <0.001 
Acting out dreams 5 0 50 <0.001 0 56 <0.001 
Crying out 5 19 47 0.03 5 64 <0.001 
Daytime sleepiness 15 29 56 0.048 43 64 0.12 
Transient LOC 0 0 3 1 0 3 1 
Insomnia 20 10 31 0.10 25 22 1 
Restless legs 15 24 25 0.92 10 20 0.46 
Autonomic Symptoms 
Dizziness or Fainting 20 29 47 0.17 29 53 0.08 
Sensitivity to heat or cold 30 52 64 0.39 48 57 0.49 
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Urinary Incontinence 5 29 28 0.95 29 26 0.82 
Constipation 25 38 44 0.64 10 53 0.001 
Visual Symptoms 
Dry/painful eyes 35 33 38 0.71 14 25 0.50 
Double Vision 5 10 18 0.70 5 36 0.01 
Difficulty reading 5 0 18 0.07 5 17 0.24 
Misjudging Objects 5 0 35 0.002 19 58 0.004 
CTRL=Control; conc./att.=concentration/attention; LOC-loss of consciousness 
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Table 4. Median duration of key symptoms in MCI-LB and DLB 
groups at baseline assessment 
 
MCI-LB (yrs) DLB (yrs) 
Memory problems 3.0 4.0 
Fluctuating Att./Conc. 1.5 2.0 
Episodes of confusion 1.0 2.0 
Rigidity/stiffness 4.0 2.0 
Shuffling walk 1.8 1.5 
Slowness of movement 2.0 2.0 
Change in handwriting 1.0 1.5 
Drooling 0.6 1.0 
Loss of smell 17.0 10.0 
Frequent falls 1.5 1.5 
Change in posture  1.0 2.0 
Weak voice 2.0 2.0 
Seeing things not present 2.0 2.0 
Involuntary movements 2.3 10.0 
Acting out dreams 3.0 7.8 
Cried out during sleep 4.5 5.5 
Misjudging Objects 2.0 1.3 
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Table 5. Symptoms present in >50% of DLB and <20% of 
AD cases 
Fluctuating conc./att. 
Episodes of confusion 
Slack facial expression 
Drooling 
Weak Voice 
Seeing things not present 
Involuntary movements 
Acting out dreams 
Crying out during sleep 
Misjudging Objects  
 
